


APPENDIX A – Marked-up Version of Amended Claims

1. (amended) A method of treating or preventing an angiogenesis-related disorder in a patient suffering from [or predisposed to] such a disorder which comprises administering to the patient a therapeutically effective amount of 3-benzoylphenylacetic acid or derivative of the formula:



wherein

R = H, C₁₋₄ (un)branched alkyl, CF₃, SR⁴;

Y = OR', NR''R';

R' = H, C₁₋₁₀ (un)branched alkyl (un)substituted (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below),

-(CH₂)_nZ(CH₂)_n'A;

n = 2-6;

n' = 1-6;

Z = nothing, O, C=O, OC(=O), C(=O)O, C(=O)NR³, NR³C(=O), S(O)_{n2}, CHOR³, NR³;

n² = 0-2;

R³ = H, C₁₋₆ (un)branched alkyl, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below);

A = H, OH, optionally (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below), -(CH₂)_nOR³;

R'' = H, OH, OR';

X and X' independently = H, F, Cl, Br, I, OR', CN, OH, S(O)_{n2}R⁴, CF₃, R⁴, NO₂;

R⁴ = C₁₋₆ (un)branched alkyl;


m = 0-3;

m' = 0-5; and

W = O, H.

APPENDIX B – Pending Claims

1. (amended) A method of treating or preventing a neurodegenerative disorder of the retina or optic nerve head in a patient suffering from such a disorder which comprises administering to the patient a therapeutically effective amount of 3-benzoylphenylacetic acid or derivative of the formula:



wherein

R = H, C₁₋₄ (un)branched alkyl, CF₃, SR⁴;

Y = OR', NR''R';

R' = H, C₁₋₁₀ (un)branched alkyl, (un)substituted (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below),

-(CH₂)_nZ(CH₂)_{n'}A;

n = 2-6;

n' = 1-6;

Z = nothing, O, C=O, OC(=O), C(=O)O, C(=O)NR³, NR³C(=O), S(O)_{n2}, CHOR³, NR³;

n² = 0-2;

R³ = H, C₁₋₆ (un)branched alkyl, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below);

A = H, OH, optionally (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below), -(CH₂)_nOR³;

R'' = H, OH, OR';

X and X' independently = H, F, Cl, Br, I, OR', CN, OH, S(O)_{n2}R⁴, CF₃, R⁴, NO₂;

R⁴ = C₁₋₆ (un)branched alkyl;

m = 0-3;

m' = 0-5; and

W = O, H.

2. The method of Claim 1 wherein

R = H, C₁₋₂ alkyl;

Y = NR'R'';

R' = H, C₁₋₆ (un)branched alkyl, —(CH₂)_nZ(CH₂)_n'A;

Z = nothing, O, CHOR³, NR³;

R₃ = H;

A = H, OH, (un)substituted aryl (substitution as defined by X below);

X and X' independently = H, F, Cl, Br, CN, CF₃, OR', SR⁴, R⁴;

R'' = H;

R⁴ = C₁₋₄ (un)branched alkyl;

m = 0-2;

m' = 0-2;

W = H;

n = 2-4; and

n' = 0-3.

3. The method of Claim 2 wherein the 3-benzoylphenylacetic acid or derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide; 2-Amino-3-benzoylphenylacetamide; and 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide.

4. The method of Claim 1 wherein the angiogenesis-related disorder is an ophthalmic angiogenesis-related disorder.

5. The method of claim 4, wherein the 3-benzoylphenylacetic acid or derivative is topically administered to the eye.

6. The method of Claim 5 wherein the therapeutically effective amount of 3-benzoylphenylacetic acid or derivative is from about 0.001 to about 4.0% (w/v).

7. The method of Claim 4 wherein the angiogenesis-related disorder is selected from the group consisting of exudative macular degeneration; proliferative diabetic retinopathy; ischemic retinopathy; retinopathy of prematurity; neovascular glaucoma; iritis rubeosis; corneal neovascularization; cyclitis; sickle cell retinopathy; and pterygium.

8. The method of claim 1 wherein the 3-benzoylphenylacetic acid or derivative is administered orally, intravenously, in a subconjunctival injection or implant, in a sub-Tenon's injection or implant, in an intravitreal injection or implant, or in a surgical irrigating solution.

9. The method of claim 1 wherein the angiogenesis-related disorder is selected from the group consisting of prostate cancer; lung cancer; breast cancer; bladder cancer; renal cancer; colon cancer; gastric cancer; pancreatic cancer; ovarian cancer; melanoma; hepatoma; sarcoma; and lymphoma.